ACADIA Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

ACAD 37.97 +0.19 (0.50%)
price chart
Analyst Upgrades: FedEx Corporation, CSX Corporation, and ACADIA ...
Analysts are weighing in today on package delivery expert FedEx Corporation (NYSE:FDX), transportation supplier CSX Corporation (NYSE:CSX), and drugmaker ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Here's a quick roundup of today's bullish ...
Company Update (NASDAQ:ACAD): ACADIA Pharmaceuticals Reports ...
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, ...
Is a Surprise Coming for ACADIA Pharmaceuticals (ACAD) This Earnings Season?
Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. (ACAD - Snapshot Report) may be one such company.
ACADIA Pharmaceuticals Inc. (ACAD) Option Traders Are Fired Up
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are up 3.1% at $36.82 -- and earlier notched an all-time high of $37.21 -- as some speculate that a key new drug application (NDA) could be on the horizon.
ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2014 ...  MarketWatch
Closing Bell Reports: ACADIA Pharmaceuticals Inc. (ACAD), Cablevision ...  WallStreet Scope
Analyst Upgrades: J.C. Penney Company, Inc., First Solar, Inc., and ACADIA ...
Analysts are weighing in today on department store chain J C Penney Company Inc (NYSE:JCP), alternative energy issue First Solar, Inc. (NASDAQ:FSLR), and drugmaker ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Here's a quick roundup of today's ...
ACADIA Pharmaceuticals's "Buy" Rating Reaffirmed at Needham ...  sleekmoney
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and ...  MarketWatch
Is a Surprise Coming for ACADIA Pharmaceuticals (ACAD) This Earnings ...
Investors are always looking for stocks that are poised to beat at earnings season and ACADIA Pharmaceuticals Inc. (. ACAD.
HC Wainwright Pounds The Table On ACADIA Pharmaceuticals
H.C. Wainwright analyst Andrew Fein came out today with an extremely bullish call on shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), initiating a Buy rating with a price target of $50, which implies an upside of 33.5% from current levels.
Trade of the Day: Speculative ACAD Stock Could Pop 25%
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - This biopharmaceutical company develops and commercializes small molecule drugs to address unmet needs in patients with neurological and central nervous system disorders.
ACADIA Pharmaceuticals Inc. Short Interest Drops by -9.2%  Ashburn Daily
Brokerage Firm Rating Disclosure Update on ACADIA Pharmaceuticals Inc.  Wall Street Pulse
Zacks Long Term Rating Update on ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) remains a strong buy in the latest set of rankings. The counter has received an average rating of 1.25 by 8 analysts.
Analyst Rating Update on ACADIA Pharmaceuticals Inc.
Analysts at Zacks have given a short term rating of buy on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) with a rank of 2. The counter has received an average rating of 1.22 from 9 brokerage firms.